XBiotech Inc
Company Profile
Business description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
stocks
ASX dividend champions: Stocks, ETFs and LICs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,879.30 | 12.90 | -0.15% |
| CAC 40 | 8,086.00 | 31.42 | -0.39% |
| DAX 40 | 24,606.77 | 130.47 | -0.53% |
| Dow JONES (US) | 50,285.66 | 276.31 | 0.55% |
| FTSE 100 | 10,443.47 | 11.13 | 0.11% |
| HKSE | 25,596.87 | 210.35 | 0.83% |
| NASDAQ | 26,293.10 | 22.74 | 0.09% |
| Nikkei 225 | 62,820.09 | 1,135.95 | 1.84% |
| NZX 50 Index | 12,923.14 | 45.07 | 0.35% |
| S&P 500 | 7,445.72 | 12.75 | 0.17% |
| S&P/ASX 200 | 8,655.90 | 16.20 | -0.19% |
| SSE Composite Index | 4,096.17 | 18.90 | 0.46% |